Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Glioma 2Brain Neoplasms 2Thyroid Neoplasms 1Lung Neoplasms 1Histiocytosis 1Gliosarcoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Magnetic Resonance Spectroscopy 6Specimen Handling 3Nivolumab 3Fluorodeoxyglucose F18 3Cisplatin 3Cetuximab 3ulixertinib 2tipifarnib 2selpercatinib 2binimetinib 2Trastuzumab 2Surveys and Questionnaires 2Radiotherapy 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2FAPI-46 2Disulfides 2Biopsy 2vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1sargramostim 1sapanisertib 1romidepsin 1relatlimab 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Panitumumab × CNS × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡